The FDA announced that Ozempic and Wegovy supply problems had ended and set final deadlines for pharmacies to stop making compounded semaglutide: Individual pharmacy locations: Required to stop by April 22, 2025 Commercial compounding operations: Discontinue production by May 22, 2025 So, compounded semaglutide was not available after May 22, 2025, except in exceptional medical circumstances where standard formulations are ineffective
[1] [2] Like many biological medicines, Ozempic requires specific storage conditions to maintain its stability and therapeutic effectiveness
Storage, handling, and shelf life Compounded semaglutide with pyridoxine requires the same careful storage as standard compounded semaglutide
It was engineered for resistance to dipeptidyl peptidase-4 (DPP-4) degradation and for strong albumin binding, which together extend its circulating half-life
Rash or itching One thing to be mindful of when using semaglutide is the possibility of getting a rash or feeling itchy
Ozempic is semaglutide, a GLP-1 receptor agonist
